Clinical Report: 2026 ASCO Breast Cancer Highlights: persevERA

Overview

Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH, discuss the phase III persevERA trial and oral selective estrogen receptor degraders (SERDs) in metastatic breast cancer. The supplied trial summary reports that first-line giredestrant plus palbociclib produced a numerical progression-free survival improvement over letrozole plus palbociclib, but did not meet the prespecified threshold for statistical significance.

Background

Endocrine therapy combined with a CDK4/6 inhibitor is a foundational first-line approach for endocrine-sensitive metastatic hormone receptor–positive, HER2-negative breast cancer, according to the supplied guideline summary. Oral SERDs are being studied as estrogen receptor–targeted treatments in this setting and in later lines of therapy. The related SABCS 2025 material describes the lidERA trial of giredestrant in adjuvant treatment of moderate- to high-risk early breast cancer, a distinct clinical setting from metastatic disease. The available context does not provide detailed persevERA methods, participant characteristics, or numerical efficacy and safety results.

Data Highlights

Key Findings

• persevERA BC evaluated giredestrant plus palbociclib against letrozole plus palbociclib as first-line treatment for ER-positive/HER2-negative locally advanced or metastatic breast cancer.
• Investigators reported a numerical progression-free survival improvement with giredestrant plus palbociclib, but the result did not meet the prespecified threshold for statistical significance.
• The supplied context does not include the trial’s numerical progression-free survival estimates, confidence intervals, safety findings, or detailed subgroup results.
• The related lidERA trial studied adjuvant giredestrant versus standard endocrine therapy in moderate- to high-risk early breast cancer, regardless of ESR1 mutation status; the provided material does not report its results.
• The supplied guideline summary describes endocrine therapy plus a CDK4/6 inhibitor as a foundational first-line approach for endocrine-sensitive metastatic HR-positive/HER2-negative disease.

Clinical Implications

The supplied information does not establish a statistically significant progression-free survival advantage for first-line giredestrant plus palbociclib over letrozole plus palbociclib. It also does not provide sufficient trial detail to assess safety, subgroup effects, or how the result should affect individual treatment decisions.

Conclusion

The available persevERA summary reports a numerical progression-free survival improvement with giredestrant plus palbociclib that did not meet the prespecified significance threshold. Further interpretation is limited by the absence of detailed efficacy, safety, and subgroup data in the supplied material.

Related Resources & Content

1. The ASCO Post, 2026 — SABCS 2025: High-Level Review of Select Data
2. NCCN, 2026 — Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
3. CancerNetwork, 2026 — Giredestrant Plus Palbociclib Shows Numerical PFS Gain in ER+, HER2– LA/mBC
4. The ASCO Post — SABCS 2025: High-Level Review of Select Data
5. The ASCO Post — SABCS 2025: High-Level Review of Select Data
6. The ASCO Post — SABCS 2025: High-Level Review of Select Data
7. Giredestrant Plus Palbociclib Shows Numerical PFS Gain in ER+, HER2– LA/mBC
8. Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
9. Giredestrant Plus Palbociclib Shows Numerical PFS Gain in ER+, HER2– LA/mBC | CancerNetwork
10. FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer | FDA